Health ยท Democratic Republic of Congo
Ebola Outbreak in DR Congo Passes Six Months, With Over 5,500 Deaths and Spread to Eight Provinces
Six months after it was declared, the Bundibugyo-strain Ebola outbreak in DR Congo has caused more than 5,500 deaths among 11,200 confirmed cases across eight provinces. Weak contact tracing, community mistrust and armed violence hamper the response, while trials of treatments and vaccines continue.
The Ebola outbreak in the Democratic Republic of Congo has reached its six-month mark with no end in sight, now affecting eight provinces and standing as the deadliest the country has recorded.
Kinshasa and Kampala declared the outbreak on 15 May, linking it to the rarer Bundibugyo strain. The virus was first identified in the mining town of Mongwalu in Ituri province, about 50 kilometres north of Bunia. DR Congo's toll now exceeds 5,500 deaths among 11,200 confirmed cases. Uganda confirmed around 20 cases, including two deaths, and has reported none since July.
Over six months, the outbreak has grown from three health zones to 67, although about 90 percent of cases remain in Ituri and North Kivu. Around ten health zones are considered under "durable control", meaning no new case for 42 days, but the virus remains active in roughly 50 zones. Africa CDC points to recent resurgences in Fataki, Kilo, Drodro and Mahagi in Ituri, and in Beni, Butembo and Oicha in North Kivu.
Africa CDC says contact tracing is seriously inadequate and community mistrust and insecurity persist. It says 64 percent of deaths occur in the community, meaning the patients were never detected at a health facility. The agency has recorded about 60 attacks on health workers or facilities in six months. Violence by armed groups also displaces people and speeds the spread of the virus.
Julien Harneis, the UN's Ebola response coordinator, said contact follow-up is well below average on the outskirts of large cities and in rural areas where the ADF are active, because surveillance workers fear going there. He also cited fighting between the CRP and Codeco in Djugu, which he said slows the response.
Research is nonetheless advancing. The Ebo-Pep trial is testing the antiviral obeldesivir on people exposed to the virus, including at Alima-run centres in Ituri. The Partners trial is assessing the monoclonal antibody MPB 134, an antiviral, and the two combined. Only the Everbo vaccine, authorised against the Zaire strain, is currently used in DR Congo. A WHO expert group has recommended adding two Bundibugyo-specific vaccine candidates to the Tumaini trial.